Geroscience needs biomarkers that capture the progressive decline of integrated biological systems with age. Physical capacity, a direct manifestation of systemic integrity, is a core pillar of biological aging but is typically assessed through discrete clinical tests. Speech production, a complex motor act requiring coordinated respiratory, laryngeal, and articulatory control, shares fundamental physiological pathways with global physical function and may therefore serve as an accessible digital biomarker of aging. In a longitudinal cohort of 464 community-dwelling older adults (mean age 79.6 ± 8.7 years), we tested the hypothesis that changes in speech track specific changes in physical capacity. Participants underwent a 3-month adapted physical activity (APA) program. At baseline (T0) and post-intervention (T1), we performed a battery of ten objective physical tests (strength, power, endurance, gait, balance, flexibility, mobility, appendicular lean mass, fatigue) and recorded spontaneous speech during emotional autobiographical recall. Multi-layered acoustic, temporal, and linguistic features were automatically extracted. The longitudinal association was analyzed via Spearman correlations and univariate linear mixed-effects models. The APA intervention induced significant improvements in key physical domains, including mobility, gait speed, handgrip strength, and balance (all p < 0.01). These gains were specifically correlated with concurrent changes in speech features (|ρ| = 0.11–0.22). For instance, greater lower-limb strength correlated with reduced vocal shimmer and lexical diversity, while improved flexibility was associated with a lower spectral centroid and zero-crossing rate, indicating smoother phonation. Linear mixed models confirmed significant within-individual coupling between trajectories of physical function and speech dynamics. Emotional context systematically modulated these associations, revealing different speech-stress signatures under cognitive-affective load. This study provides novel longitudinal evidence that speech is a dynamic digital biomarker of domain-specific physical capacity, reflecting underlying functional integrity. The domain-specific speech-physical coupling suggests that speech analysis can serve as a novel, integrative tool for remote monitoring of aging trajectories and the functional efficacy of interventions targeting the age-related physiological decline. Speech as a longitudinal digital biomarker of physical aging.
The gut microbiota has emerged as a central regulator of the gut–brain axis, profoundly influencing neural, immune, and metabolic homeostasis. Increasing evidence indicates that disturbances in microbial composition and function contribute to the onset and progression of neurodegenerative diseases (NDs) through mechanisms involving neuroinflammation, oxidative stress, and impaired neurotransmission. Gut dysbiosis is characterized by a loss of microbial diversity, a reduction in beneficial commensals, and an enrichment of pro-inflammatory taxa. These shifts alter intestinal permeability and systemic immune tone, allowing microbial metabolites and immune mediators to affect central nervous system (CNS) integrity. Metabolites such as short-chain fatty acids (SCFAs), tryptophan derivatives, lipopolysaccharides (LPS), and trimethylamine N-oxide (TMAO) modulate blood–brain barrier (BBB) function, microglial activation, and neurotransmitter synthesis, linking intestinal imbalance to neuronal dysfunction and cognitive decline. Disruption of this gut–brain communication network promotes chronic inflammation and metabolic dysregulation, key features of neurodegenerative pathology. SCFA-producing and tryptophan-metabolizing bacteria appear to exert neuroprotective effects by modulating immune responses, epigenetic regulation, and neuronal resilience. The aim of this work was to comprehensively explore the current evidence on the bidirectional communication between the gut microbiota and the CNS, with a focus on identifying the principal molecular, immune, and metabolic mechanisms supported by the strongest and most consistent data. By integrating findings from recent human studies, this review sought to clarify how microbial composition and function influence neurochemical balance, immune activation, and BBB integrity, ultimately contributing to the onset and progression of neurodegenerative processes. Collectively, these findings position the gut microbiota as a dynamic interface between the enteric and CNS, capable of influencing neurodegenerative processes through immune and metabolic signaling.
OBJECTIVE:To validate a newly proposed anatomic staging system for choroidal and ciliary body melanoma, based on tumour volume estimated from routine clinical measurements, and compare its prognostic performance with the American Joint Committee on Cancer (AJCC) 8th edition classification. DESIGN:A retrospective, multicentre cohort study. PARTICIPANTS:A total of 5 410 consecutive patients diagnosed with choroidal and/or ciliary body melanoma at 6 European ocular oncology centres. METHODS:Tumours were staged according to both classifications. Prognostic performance was evaluated using competing risk regression, Cox regression, Kaplan-Meier survival analyses, and net reclassification improvement. RESULTS:The new classification showed better prognostic discrimination than the AJCC system, with a net reclassification improvement of 23%. In competing risk regression, it produced a higher Wald statistic (761 vs 628) and a subdistribution hazard ratio of 1.42 versus 1.22. Cox regression for melanoma-related mortality demonstrated higher hazard ratios, peaking at 24 for the new model compared with 13 for the AJCC classification. Cumulative incidence analyses revealed 15-year metastatic death rates ranging from 7% to 76% with the new system versus 11% to 69% with AJCC, widening the absolute range by 11 percentage points. CONCLUSIONS:This large international validation study demonstrates that the new volume-based classification provides more accurate prognostic stratification for choroidal and ciliary body melanoma. Its improved risk discrimination, using readily available clinical measurements, supports its applicability in clinical practice and potential utility for guiding follow-up and resource allocation.